# ImmunoPrecise Antibodies Ltd. (IPA)

Source: https://www.quantisnow.com/company/IPA
Generated: 2026-11-04T00:06:23.184Z

- Ticker: IPA
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- Website: immunoprecise.com

## About

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has a research collaboration agreement with Pierre Fabre S.A for antibody discovery. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.

## Latest IPA news and filings

- 2026-05-18 13:02 UTC [Leadership Update] [InterVenn Appoints Industry Leaders Alec Ford and Mitch Levine to Board of Directors](https://www.quantisnow.com/insight/intervenn-appoints-industry-leaders-alec-ford-and-mitch-levine-to-6559459)
- 2026-05-18 12:34 UTC [The Biology Came First.](https://www.quantisnow.com/insight/the-biology-came-first-6559337)
- 2025-09-03 13:21 UTC [SEC Form 6-K] [SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-immunoprecise-antibodies-ltd-6187394)
- 2025-09-03 12:48 UTC [ImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to "HYFT"](https://www.quantisnow.com/insight/immunoprecise-rebrands-as-mindwalk-announces-nasdaq-ticker-change-to-hyft-6187283)
- 2025-09-02 12:58 UTC [SEC Form 6-K] [SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-immunoprecise-antibodies-ltd-6185202)
- 2025-09-02 12:01 UTC [ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 27th Annual Global Investment Conference in New York](https://www.quantisnow.com/insight/immunoprecise-antibodies-to-participate-at-hc-wainwrights-27th-annual-global-6184905)
- 2025-08-27 13:49 UTC [SEC Form 6-K] [SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-immunoprecise-antibodies-ltd-6180405)
- 2025-08-27 12:22 UTC [ImmunoPrecise Advances AI Discovered and Developed Universal Dengue Vaccine Initiative: Moves into Preclinical Antibody Generation](https://www.quantisnow.com/insight/immunoprecise-advances-ai-discovered-and-developed-universal-dengue-vaccine-initiative-6180192)
- 2025-08-06 13:45 UTC [SEC Form 6-K] [SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-immunoprecise-antibodies-ltd-6149585)
- 2025-08-06 12:00 UTC [ImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate Bio-Native AI Innovation](https://www.quantisnow.com/insight/immunoprecise-antibodies-ltd-divests-netherlands-facilities-to-avs-bio-to-6149307)
- 2025-08-06 12:00 UTC [Leadership Update] [AVS Bio, an Arlington Capital Partners Portfolio Company, Expands Antibody Discovery and Protein Production Capabilities With Acquisition of ImmunoPrecise Antibodies Europe From ImmunoPrecise Antibodies Ltd.](https://www.quantisnow.com/insight/avs-bio-an-arlington-capital-partners-portfolio-company-expands-antibody-6149265)
- 2025-08-01 13:25 UTC [SEC Form 6-K] [SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-immunoprecise-antibodies-ltd-6142476)
- 2025-07-29 12:30 UTC [SEC Form 6-K] [SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-immunoprecise-antibodies-ltd-6135608)
- 2025-07-29 12:28 UTC [Earnings Date] [ImmunoPrecise Antibodies (IPA) Reports Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDA](https://www.quantisnow.com/insight/immunoprecise-antibodies-ipa-reports-full-fiscal-year-2025-results-record-6135559)
- 2025-07-29 12:00 UTC [SEC Form 20-F filed by ImmunoPrecise Antibodies Ltd.](https://www.quantisnow.com/insight/sec-form-20-f-filed-by-immunoprecise-antibodies-ltd-6135504)
- 2025-07-24 13:40 UTC [SEC Form 6-K] [SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-immunoprecise-antibodies-ltd-6131160)
- 2025-07-24 12:22 UTC [ImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the Clinic](https://www.quantisnow.com/insight/immunoprecise-releases-new-findings-showing-lensai-quickly-flags-anti-drug-antibody-risklong-6130944)
- 2025-07-21 13:50 UTC [SEC Form 6-K] [SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-immunoprecise-antibodies-ltd-6126492)
- 2025-07-21 12:28 UTC [Leadership Update] [ImmunoPrecise Appoints Healthcare Data Visionary Jeff Fried to Advisory Board](https://www.quantisnow.com/insight/immunoprecise-appoints-healthcare-data-visionary-jeff-fried-to-advisory-board-6126304)
- 2025-07-16 12:05 UTC [Earnings Date] [IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025](https://www.quantisnow.com/insight/ipa-to-report-financial-results-and-recent-business-highlights-for-6121488)
- 2025-07-14 13:31 UTC [SEC Form 6-K] [SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-immunoprecise-antibodies-ltd-6118926)
- 2025-07-14 12:01 UTC [ImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price Requirement](https://www.quantisnow.com/insight/immunoprecise-regains-compliance-with-nasdaq-minimum-bid-price-requirement-6118658)
- 2025-07-07 13:16 UTC [SEC Form 6-K] [SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-immunoprecise-antibodies-ltd-6112382)
- 2025-07-07 13:00 UTC [Leadership Update] [ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors](https://www.quantisnow.com/insight/immunoprecise-antibodies-appoints-industry-veteran-jon-lieber-to-board-of-6112344)
- 2025-07-03 13:40 UTC [SEC Form 6-K] [SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-immunoprecise-antibodies-ltd-6110298)
- 2025-06-24 12:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-immunoprecise-antibodies-ltd-6096686)
- 2025-06-24 11:02 UTC [ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ Platform Powered by Patented HYFT® Technology](https://www.quantisnow.com/insight/immunoprecise-advances-universal-dengue-vaccine-confirming-safety-immune-activation-and-6096527)
- 2025-06-12 12:25 UTC [SEC Form 6-K] [SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-immunoprecise-antibodies-ltd-6083235)
- 2025-06-12 12:01 UTC [AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies](https://www.quantisnow.com/insight/ai-designed-glp-1-peptides-from-immunoprecise-antibodies-surpass-semaglutide-in-receptor-6083198)
- 2025-06-05 12:11 UTC [SEC Form 6-K] [SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-immunoprecise-antibodies-ltd-6073775)
- 2025-06-05 12:01 UTC [ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery](https://www.quantisnow.com/insight/immunoprecise-announces-ai-driven-breakthrough-in-universal-dengue-vaccine-discovery-6073749)
- 2025-05-21 12:49 UTC [ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts](https://www.quantisnow.com/insight/immunoprecise-antibodies-engages-core-ir-to-enhance-investor-engagement-efforts-6051787)
- 2025-05-21 12:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-immunoprecise-antibodies-ltd-6051673)
- 2025-05-20 12:28 UTC [Conference Announcement] [ImmunoPrecise Antibodies (IPA) to Present at Maxim Group's 2025 Virtual Tech Conference](https://www.quantisnow.com/insight/immunoprecise-antibodies-ipa-to-present-at-maxim-groups-2025-virtual-6049567)
- 2025-05-12 13:55 UTC [SEC Form 6-K] [SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-immunoprecise-antibodies-ltd-6032084)
- 2025-05-12 12:01 UTC [IPA's LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed](https://www.quantisnow.com/insight/ipas-lensai-platform-delivers-x-raylevel-epitope-mapping-insights-in-hours-6031809)
- 2025-04-11 17:43 UTC [SEC Form 6-K] [SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-immunoprecise-antibodies-ltd-5985399)
- 2025-04-11 12:40 UTC [ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing Methods](https://www.quantisnow.com/insight/immunoprecise-antibodies-highlights-alignment-of-proprietary-ai-driven-platform-lensai-with-5985187)
- 2025-04-09 23:45 UTC [SEC Form 6-K] [SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-immunoprecise-antibodies-ltd-5983385)
- 2025-03-28 15:17 UTC [SEC Form 6-K] [SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-immunoprecise-antibodies-ltd-5964412)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/IPA
- Earnings history: https://www.quantisnow.com/earnings/IPA
- Dividend history: https://www.quantisnow.com/dividends/IPA
- Insider transactions: https://www.quantisnow.com/insiders/IPA
- Options chain: https://www.quantisnow.com/options/IPA
- SEC 8-K filings only: https://www.quantisnow.com/company/IPA/8-k
- RSS and alerts for IPA: https://www.quantisnow.com/docs/rss-feeds.md